Stock Price: $3.50
Analyst Rating: STRONG BUY

HeartSciences Stock Rated “Strong Buy” by Analysts

HeartSciences (Nasdaq: HSCS) is advancing a breakthrough AI-powered ECG designed to make heart disease detection faster and more accurate. Analysts have issued “Strong Buy” ratings with price targets above today’s stock price.
Invest Now
Each $3.50 Unit Includes One Convertible Preferred Share and a Warrant to Purchase an Additional Common Share at $5.00

Access investment units with convertible preferred stock and warrants at a fixed price of $3.50

Ticker
HSCS
Sector
Medical AI
Offer Type
Investment Unit
Preferred stock + warrant
Unit Price
$3.50
Warrant exercise price: $5.00
Analyst Sentiment
1-Year Analyst Target

Analyst Confidence Signals 6X Near-Term Upside Potential

Stock analysts see upside in HeartSciences based on the company’s:
Imminent FDA submission
Patented AI-powered
ECG technology
Focus on early heart disease detection—a $30 billion dollar unmet need
Comps: Shockwave Medical focuses on a smaller ECG market and is valued at $4 billion
Invest Now

Special Terms Only Available Through This Offering

Investors Receive More Than Common Stock
Convertible preferred
shares
Warrant to purchase a common share at $5.00
Each $3.50 unit includes one convertible preferred share and one warrant to purchase an additional common share at $5.00.

Detecting Heart Disease Sooner With AI

HeartSciences is reimagining the ECG–the most widely used heart test worldwide. Its technology and AI-driven software aim to detect heart disease earlier and more accurately.

HeartSciences is preparing for commercialization in the U.S. and abroad, with the first commercial customer signed and early commercial use of its device taking place in several European centers.
Help Close the Diagnostic Gap in Healthcare

Breakthrough Tech + Strategic Timing

Heart disease is the #1 cause of death globally. But most diagnostic tools catch it too late. HeartSciences is entering a massive market with disruptive tech—and the company is at a key inflection point.
Analysts agree the stock is undervalued
FDA clearance could be a major catalyst
This offering gives investors a strategic entry point.

Key Milestones:

May 1, 2025

HeartSciences Announces Launch of MyoVista Insights™ Platform

May 29, 2025

HeartSciences Signs First MyoVista Insights™ Platform Customer

June 3, 2025

US Patent Granted for ECG Assessment of Heart Function (44th patent)

June 3, 2025

FDA Breakthrough Device Designation received

June 4, 2025

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Coming up

Summer 2025 - FDA Submission

Company Updates

FAQs

 

What Is the Unit Priced At?

The public offering price of the Unit is $3.50. Each investment unit includes:
✔ 1 Convertible Preferred Share (convertible into 1 Common Share)
✔ 1 Common Stock Warrant (allowing the purchase of 1 more share of Common Stock at a fixed price)

 

Are the Units Registered Securities?

The Common Stock receivable following conversion of the Preferred Shares, or exercise of the warrants, have been registered and could be traded immediately.

 

Will the Preferred Shares Trade?

The Preferred Shares do not trade, but each Preferred Share is convertible at any
time into one share of Common Stock that trades on Nasdaq under the symbol
“HSCS”. The Common Stock has been registered, so it would be immediately tradable
following conversion.

 

What Is a Warrant?

A warrant is a financial instrument that gives the holder the right—but not the obligation—to purchase our company's stock at a $5.00 strike price for three years. Stock warrants are often used by companies to raise capital or sweeten deals for investors, as they allow investors to get extra shares at a fixed price and leverage potential stock price increases.

 

Do I Have to Be An Accredited Investor to Purchase Units?

No, you do not need to be an accredited investor.

 

What Is the Minimum Investment Amount?

The minimum investment amount is $675, or 193 Units.

 

Where Are My Preferred Shares Held?

The Preferred shares will be issued in book-entry form with the transfer agent Equiniti Trust Company. When the Company holds a closing, the transfer agent will set up an account for each investor (there will be a separate account for common and warrant). Investors will be notified by mail with their account information and how to set up their login access to Shareholder Central (Equiniti does not send emails to shareholders).

Once the account is established, please log in to your account at https://equiniti.com/us/ast-access/individuals/ to view, print or download your DRS Statement. Under Shareholder Central, click on login. Enter username and password. An MFA code will be emailed to the email address used at the time of initial registration. Enter the 6-digit code on the screen and you will be guided to the account landing page. On the account landing page, towards the bottom left of the page, click on “Account Balance Letter” and it will allow you to download a current data account statement. Shareholder Central will now allow you to retrieve historical data statements. Other documents in the account are available under “Statements, Tax and Other Documents” tab.

 

How do I convert my Preferred Shares to common stock?

Investors will need to complete the Notice of Conversion (Click Link Here). It is important to complete accurately the number of preferred shares held and the number of shares to convert. Note Preferred Shares convert 1:1 into common stock. Please be sure to sign the document. Investors can email the company a copy of the Notice of Conversion to danielle.watson@heartsciences.com for conversion requests and or they can email Equiniti directly at PortalConversion@equiniti.com

 

Can the Company Force Conversion of the Preferred Shares?

Upon the occurrence of any of the following events, the Company shall have a right to direct the mandatory conversion of the Series D Preferred Stock: (a) a change in control of our Company, (b) if the price of the Common Stock closes at or above $5.00 per share for 10 consecutive trading days, or (c) if we consummate a firm commitment public offering of Common Stock for gross proceeds of at least $15 million at an offering price per share equal to or greater than $5.00.

 

How Do the Shares and Warrants Convert to Common Stock?

Each share of the Preferred is convertible into one share of Common Stock at any time at the holder’s option. Each warrant can be exercised into 1 share of Common Stock at $5.00. All you need to do is notify the transfer agent you wish to convert your shares or exercise your warrants and you can transfer and trade with your broker.

 

If the Common Stock Is Above $3.50, What Happens?

You can convert your Preferred Stock into Common Stock at any time and, if you choose, have your broker sell it—capturing the difference between the sale price and $3.50. Once you convert, you will still retain your warrant.

 

How Do I Pay for the Shares?

After you complete the subscription by clicking “Invest Now,” you may pay the escrow agent by credit card, wire transfer, or ACH transfer.

 

How Long Do I Have to Wait to Sell My Shares After I Purchase?

Shares in the offering are eligible for resale immediately; however, you may initially only transfer those shares that have been converted from Preferred to Common Stock.

 

How Do I Transfer My Shares to My Broker to Trade?

Once you convert to Common Stock, you can easily transfer your shares to your broker. You will not be able to transfer the Preferred Shares, but you may convert them at any time. There is no cost or annual fee to keep your shares with Equiniti Trust Company, LLC if you prefer not to move them to a brokerage.

 

How Do I Purchase the Company’s Common Stock Now?

You can purchase shares directly through your broker. The Company is listed on NASDAQ under the symbol HSCS.

 

Who Is the Company’s Independent Auditor?

Haskell & White LLP
Website: https://www.hwcpa.com/

 

How Do I Contact HSCS Investor Relations?

Integrous Communications
Mark Komonoski, Partner
Phone: 877-255-8483
Email: mkomonoski@integcom.us

 

What Is a Transfer Agent?

A transfer agent maintains a record of ownership, including contact information for shareholders.

 

Who Is the Company’s Transfer Agent?

Equiniti Trust Company, LLC (formerly AST)
Website: https://equiniti.com/us/ast-access
Phone: 1-800-937-5449 (toll free) or 1-718-921-8124
Email: HelpAST@equiniti.com

 

How Do I Get Additional Information on the Offering?

For more details, please read the Form 1-A here in its entirety.

 

What Kind of Shares Are You Issuing?

The Company is offering, on a “best efforts’ basis, up to 4,285,714 Units, each Unit consisting of one (1) share of  Series D Convertible Preferred Stock and one (1) warrant to purchase common stock. The Units will be sold at an offering price of $3.50 per Unit. The warrants are exercisable at a price of $5.00 for one (1) share of Common Stock.

 

Where Can I Find The Company’s SEC Filings?

All of HeartSciences’ regulatory filings, including financial reports, can be found here:

 

How Much Are You Raising?

The Units will be sold at an offering price of $3.50 per Unit, for a maximum offering amount of  $15,000,000.

 

How Will I Get A Return On My Investment?

Investing in startups is risky and there is no guarantee you will get a return on your investment. However, the fact that our common stock is listed on Nasdaq (Nasdaq: HSCS) opens up an opportunity for you to convert your preferred shares into common stock providing an exit in cash (if you choose to sell the common stock) or desire to hold a more liquid asset. If the value of our Company grows, then you have a higher potential of making a profit on your investment.You are investing in a pre-revenue company selling an emerging technology. Success will be measured in progress towards commercialization and growing revenue and profitability.

 

When Will I Receive My Shares?

Shares will be issued through the transfer agent, Equiniti Trust Company, LLC after the investment funds clear.

 

Are There Higher Fees If You Invest via Credit Card vs. ACH?

No, costs are the same, regardless of how you invest.

 

How Will I (Investor) Make Money?

The Company expects to achieve many milestones in 2025, including FDA clearance which would be expected to see an increase in our share price. We are already listed on Nasdaq so there is the ability to buy and sell our Common Stock. Additionally, the warrants offer the ability to buy further shares at a fixed price.

 

How Do I Know People Will Buy This Solution?

The FDA has already created a new clinical pathway specifically for AI-ECG, the American Medical Association issued new reimbursement codes and in early 2025 Medicare agreed to start paying for use of AI-ECG. Mayo Clinic is expected to be one of the early adopters and has already used the reimbursement code for AI-ECG tens of thousands of times.

 

Are There More Opportunities Ahead?

We are at the beginning of what is expected to be a new era for an ECG and its clinical capabilities and we expect many new opportunities. We would expect to bring a portfolio of valuable algorithms into clinical practice and have plans to roll-out further upgrades for both the MyoVista wavECG device and MyoVista Insights cloud-platform. We also have a number of international opportunities and relationships.

 

Why Didn't A Bigger Company Do This Already?

The big companies tend to focus on maximizing sales of existing products rather than innovation of new ones. Additionally, the data required to develop new algorithms is held by clinical institutions rather than companies and is a barrier to entry and why our clinical collaborations and partnerships in this field are valuable.

 

How do you plan to use the proceeds from this funding round?

Proceeds from this offering will be used to fund the Company achieving regulatory clearances for its products as well as on-going R&D and clinical activities, sales and marketing and general corporate purposes.

 

What is the current valuation of the Company?

Based on the $3.50 conversion price the pre-money valuation is $4 million.

 

Why Should I Invest?

Your support and commitment will help HeartSciences shape the future of heart healthcare and early detection of heart disease.

 

How long are you expecting the company to operate before needing another round?

If we are able to raise the full amount it is anticipated that this will allow us to get our first products to market. We would expect to need additional capital at that time to market and sell the product. 

 

What is the exit plan for the company?

We are a Nasdaq listed company. Investors can convert their Preferred Stock to Common Stock and are free to trade it at any time. We also anticipate that as we get into sales the Company may well be attractive for acquisition by a larger medical devices company.

 

What markets are you currently focused on?

We are a medical technology company focused on making the ECG (also known as an EKG) significantly more clinically valuable so that it can detect heart disease earlier. The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.

 

How many investors do you have already?

We are a listed company with over 3,000 holders of our common stock.

 

Will you be paying out dividends to investors?

We do not intend to pay dividends in the near future.

 

What is HeartSciences’ core business?

HeartSciences is focussed on making the ECG (also known as an EKG) far more clinically valuable so that so that it can detect heart disease earlier. We are developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting worldwide, either via our MyoVista Insights™ cloud-platform using one of the millions of ECG devices currently in clinical use or via our MyoVista® wavECG™ Device.

 

Where are your headquarters located?

Southlake, Texas

 

How many employees does your Company have?

15

 

When will the Company expand into additional markets and which ones?

In addition to the USA, we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets.

 

Do you plan to expand internationally?

Yes we already have established clinical relationships in Europe, Australia and India and have distributors appointed in those markets. We intend to market our products in those areas regulatory clearances.

 

Can you share the roadmap for the next 3-4 years and when you expect to become profitable?

Our business model is based on valuable recurring revenues charging a fee for single use supplies, use of algorithms and/or a SaaS subscription which are all at high margin. We expect revenue to start in 2026 and increase substantially as products are adopted and there is an installed user base. Today, more than 100 million ECG tests are performed in the US alone and accordingly, we expect to become profitable much earlier than most medical device companies.

 

Do you plan on licensing your technology?

Yes, that is one of several potential revenue streams.

 

How many patents do you have?

43 patents.

 

What does your path to profitability look like?

See #18 above

 

Who are your competitors? What are your advantages against them?

The traditional ECG market is dominated by large medical device manufacturers like GE Healthcare. However, traditional ECGs are decades old technology. AI-ECG is a fast emerging new field with a handful of early stage companies. We have been around longer and have significantly greater experience and relationships in this field than most other companies. We are the only company developing holistic device and cloud-native device agnostic AI-ECG solutions which will enable us to deliver AI-ECG solutions across a wide range of healthcare settings, from large hospital systems to simple nurse-led mobile testing services

 

Who is the main audience target for your product/service?

The ECG is one of the most ubiquitous medical tests in the world and performed millions of times a week across healthcare settings including in hospitals, doctor’s offices, other healthcare providers, and retail and screening clinics.

 

Are you looking to partner with other companies?

We are already partnering with several healthcare institutions and overtime see enormous opportunities for partnering with other companies. Either alternative/ telehealth ECG hardware (such as the Apple watch) or the MyoVista Insights platform providing an AI-ECG marketplace to host third party algorithms.

 

What have been the main challenges in developing your service/product and how have they been mitigated?

The development of AI-ECG algorithms requires access to significant health care data. We have collaborated with many healthcare institutions such in the US, the UK, Denmark and Australia and licenced considerable IP from Mount Sinai, New York which is one of the world’s leading cardiology healthcare institutions.